EU's graphic holiday guide to sex is full of holes
Published by the European Centre for Disease Prevention and Control (ECDC), the EU's public health agency, the online guide offers explicit advice aimed primarily at men who have sex with men.
It includes foremost tips on how to avoid infections that spread among men who have sex with men, such as mpox and Shigella – and recommends that those engaging in such practices "not share sex toys" and "use disposable gloves for fingering or fisting".
Noticeably absent is detailed guidance for the population at large and their sexual health needs.
Chlamydia, for example, is mentioned only once in a list with gonorrhoea and syphilis despite being Europe's most reported sexually transmitted bacterial infection. Though it frequently goes undetected due to its lack of symptoms, it can lead to serious complications like infertility, disproportionately affecting women.
Carsten Müller, a prominent German sex educator, said the guide, which urges 'everyone to be informed', risks leaving much of the population underserved.
'If we focus on sex between men, it leaves a lot of room for discrimination. And as soon as the topic turns to mpox, anyone who isn't a man who has sex with men immediately starts to feel defensive, saying, 'That doesn't affect me,'' he added. 'Highway to hell' Leaving chlamydia and other mainstream infections largely unaddressed is difficult to overlook, especially in light of ECDC data showing a general rise in STI cases across Europe.
Gonorrhoea cases, for instance, increased by 321% between 2014 and 2023. While MSM accounted for 58% of them, infection rates among young women aged 20–24 hit 72 per 100,000 – a high figure given the rate for all men that stands at 131 per 100,000.
Yet the ECDC's summer guide offers little practical information for a general audience beyond the standard call for 'consistent condom use for vaginal, anal, and oral sex'. For example, the recommendation to use dental dams focuses exclusively on "oral-anal sex', with no mention of their use during oral sex between female partners or heterosexual sex.
For those seeking more comprehensive or practical advice – such as how to adapt a condom for protection during oral sex – resources like the website of the US Centers for Disease Control and Prevention may be more helpful.
Müller added that the ECDC's focus reflects a broader problem in European sex education: It's primarily directed at young people, even as STI rates rise among older adults.
Genital herpes – an incurable infection that ranks among the most common STIs globally – is not mentioned at all, even though, according to the WHO, someone is infected with the virus every second.
When asked by Euractiv why herpes was omitted, an ECDC spokesperson answered: 'Herpes is not a notifiable disease (as per decision by the European Commission), therefore this is not a disease that the ECDC actively monitors.' The spokesperson referred those seeking guidance to the WHO's website. What about HPV? Human Papillomavirus (HPV) was also absent from the summer guide, despite several strains of the virus being linked to cervical, penile, throat, and other cancers.
When asked about this by Euractiv at an event on the topic, an ECDC expert who had just presented on HPV vaccination and screening struggled to offer practical advice.
Before the ECDC expert could find an answer, Dr. Rui Medeiros, head of education at the Portuguese League Against Cancer, stepped in with a blunt assessment: 'Ultimately, every act is at your own risk. It's like crossing a red light – you might get away with it, or you might not.'
For Müller, the ECDC's call for 'fostering open communication' is also vague, noting that "we need to help people talk about sex and the risks that come with it'.
He suggests including practical conversation starters in the guide, such as: 'I feel like having sex with you – let's talk about how to make it safe' – a line that would not be too difficult to translate into all 24 official EU languages (or very effective at a beachside bar).
(de, vib, jp, mk)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
2 days ago
- Euractiv
EU's graphic holiday guide to sex is full of holes
The EU's new guide on how to stay sexually healthy during the holiday season isn't for everyone. Published by the European Centre for Disease Prevention and Control (ECDC), the EU's public health agency, the online guide offers explicit advice aimed primarily at men who have sex with men. It includes foremost tips on how to avoid infections that spread among men who have sex with men, such as mpox and Shigella – and recommends that those engaging in such practices "not share sex toys" and "use disposable gloves for fingering or fisting". Noticeably absent is detailed guidance for the population at large and their sexual health needs. Chlamydia, for example, is mentioned only once in a list with gonorrhoea and syphilis despite being Europe's most reported sexually transmitted bacterial infection. Though it frequently goes undetected due to its lack of symptoms, it can lead to serious complications like infertility, disproportionately affecting women. Carsten Müller, a prominent German sex educator, said the guide, which urges 'everyone to be informed', risks leaving much of the population underserved. 'If we focus on sex between men, it leaves a lot of room for discrimination. And as soon as the topic turns to mpox, anyone who isn't a man who has sex with men immediately starts to feel defensive, saying, 'That doesn't affect me,'' he added. 'Highway to hell' Leaving chlamydia and other mainstream infections largely unaddressed is difficult to overlook, especially in light of ECDC data showing a general rise in STI cases across Europe. Gonorrhoea cases, for instance, increased by 321% between 2014 and 2023. While MSM accounted for 58% of them, infection rates among young women aged 20–24 hit 72 per 100,000 – a high figure given the rate for all men that stands at 131 per 100,000. Yet the ECDC's summer guide offers little practical information for a general audience beyond the standard call for 'consistent condom use for vaginal, anal, and oral sex'. For example, the recommendation to use dental dams focuses exclusively on "oral-anal sex', with no mention of their use during oral sex between female partners or heterosexual sex. For those seeking more comprehensive or practical advice – such as how to adapt a condom for protection during oral sex – resources like the website of the US Centers for Disease Control and Prevention may be more helpful. Müller added that the ECDC's focus reflects a broader problem in European sex education: It's primarily directed at young people, even as STI rates rise among older adults. Genital herpes – an incurable infection that ranks among the most common STIs globally – is not mentioned at all, even though, according to the WHO, someone is infected with the virus every second. When asked by Euractiv why herpes was omitted, an ECDC spokesperson answered: 'Herpes is not a notifiable disease (as per decision by the European Commission), therefore this is not a disease that the ECDC actively monitors.' The spokesperson referred those seeking guidance to the WHO's website. What about HPV? Human Papillomavirus (HPV) was also absent from the summer guide, despite several strains of the virus being linked to cervical, penile, throat, and other cancers. When asked about this by Euractiv at an event on the topic, an ECDC expert who had just presented on HPV vaccination and screening struggled to offer practical advice. Before the ECDC expert could find an answer, Dr. Rui Medeiros, head of education at the Portuguese League Against Cancer, stepped in with a blunt assessment: 'Ultimately, every act is at your own risk. It's like crossing a red light – you might get away with it, or you might not.' For Müller, the ECDC's call for 'fostering open communication' is also vague, noting that "we need to help people talk about sex and the risks that come with it'. He suggests including practical conversation starters in the guide, such as: 'I feel like having sex with you – let's talk about how to make it safe' – a line that would not be too difficult to translate into all 24 official EU languages (or very effective at a beachside bar). (de, vib, jp, mk)
Euractiv
7 days ago
- Euractiv
Sweden backs EU-wide patent reform to support drug innovation
Hoping to support pharmaceutical innovation and competitiveness, Stockholm is advocating for a Unitary Patent System. Sweden is one of eleven EU Member States pushing the Danish Presidency to finalise an EU system for enhanced patent protection for medicines. Supplementary Protection Certificates (SPCs) have been in place for several decades in the European Union. They are an intellectual property right that grants a patentholder an additional five years of patent protection, primarily for medicine patents. So far, each Member State has to implement such protection nationally, resulting in varying outcomes between countries. However, a unitary system was proposed by the EU Commission in 2023. Under this proposal, a unitary SPC would be relevant in the 18 EU states that have currently joined the so-called Unitary Patent System. 'A unitary SPC would be an important piece of the puzzle to finalise the Unitary Patent System and a reform that would boost innovation and competitiveness', Louise Petrelius, a senior advisor at the Swedish Ministry of Justice, told Euractiv. She explains that the system is expected to streamline the extension of patent protection for both medicinal and plant protection products (e.g. pesticides) in the EU by introducing a single, unified procedure across participating member states. 'This aims to simplify the current system, which requires separate applications in each country, reducing costs and administrative burden for applicants.' Longer time to market According to Petrelius, SPCs aim to compensate patent holders for the extra time it takes to bring their products to market, due to the compulsory lengthy testing and clinical trials required prior to obtaining regulatory marketing approval. The protection for patents in the EU is 20 years. An SPC could extend such a patent right for a maximum of five years. As the SPC mechanism extends the market exclusivity of a patented medicine beyond the initial patent term, it could delay the entry of generic or biosimilar competition and maintain higher prices for a longer period in the EU. According to the Swedish Intellectual Property Office (PRV), companies producing generics and biosimilars are only allowed to start manufacturing and storing a medicine during the extra five-year protection period if their products are to be exported outside the EU. Civil society organisations, as Médecins Sans Frontières (MSF), have previously called upon the EU to abolish the SPC mechanism, saying it contributes 'to high drug prices and hinders access to essential medicines by delaying the availability of generic and biosimilar alternatives'. No price analysis Johan Pontén, International Coordinator at the Swedish Dental and Pharmaceutical Benefits Agency (TLV), told Euractiv that 'TLV agrees with the Swedish government that a centralised SPC system creates more uniform and simpler management within the EU, which is positive,' adding, however: 'We have not been tasked with analysing how a changed system could affect the prices of medicines and therefore cannot comment on it'. Meanwhile, according to the Swedish Ministry of Justice, there is no ongoing discussion in the EU that links higher prices to the SPC proposal. 'Since the question of the existence of SPCs is not subject to negotiation, it is not discussed in this project. In general, my view is that Sweden is in favour of a system that promotes innovation and attractiveness on the pharmaceutical side, where intellectual property protection is an important component,' Petter Söderbäck, also a senior legal advisor at the Swedish Ministry of Justice, told Euractiv. Euractiv has requested a comment from the Danish Presidency, but has not received a response so far. [Edited by Vasiliki Angouridi]
Euractiv
06-08-2025
- Euractiv
Big Pharma in ‘active discussions' with Trump on pricing
Several pharmaceutical companies have commented on US President Donald Trump's demand to cut drug prices and impose tariffs, citing "high volatility" but signalling willingness for "constructive" cooperation. Trump last week told major pharmaceutical firms to lower prices in the US or face penalties, aiming to bring relief to Americans facing far higher medicine costs than in other countries. "We continue to observe high volatility," Bayer CEO Bill Anderson commented on the US trade policy, adding that it remains unclear whether ongoing investigations in the sector will lead to additional pharma tariffs. He also commented on Trump's announcement that tariffs on pharmaceuticals could reach 250% in the coming years, intended to push companies to relocate production to the US. "It's hard to speculate about what the impact would be next year until we have a more concrete picture of exactly what the trade policy will be," he added. Pfizer CEO Albert Bourla said his company is in 'very active discussions' over Trump's request concerning most-favoured-nation pricing, according to news website FiercePharma . Bourla said he had personally spoken to the president but did not share many details. German pharmaceutical company Boehringer Ingelheim issued a statement on Tuesday, striking a similarly constructive tone: 'We will continue to work constructively with governments, regulatory authorities, and patient organizations to ensure that patients have access to affordable medicines and that medical innovation for life-saving treatments remains possible.' Regeneron CEO Leonard Schleifer also commented on the letters, agreeing with Trump that European countries are not paying their fair share for drugs. "The solution is not simply to lower prices in the US without some balancing adjustment in Europe, because otherwise there will be no innovation,' Schleifer said. (cs, de)
